PSA level at ADT initiation, Gleason score, stage, PSA nadir, time to PSA nadir, and treatment modality were all associated with prostate cancer-specific mortality (PCSM) (P ≤ 0.002). This evidence concerns the gene KLK3 and Familial prostate cancer.